Table 1 Baseline characteristics of the patients
Characteristic | Nicotine replacement therapy (N = 21) | Control group (N = 26) |
|---|---|---|
Age, years, mean (SD) | 60.1 (10.55) | 65. 2 (9.13) |
Male sex, n (%) | 12 (57) | 16 (62) |
BMI (m2/kg), mean (SD) | 26.4 (6.75) | 27.8 (5.95) |
Charlson Comorbidity Index, median (IQR) | 1 (0–1) | 1 (0–2.25) |
APACHE-II score, mean (SD) | 19.0 (5.03) | 21.1 (8.60) |
APACHE-IV score, mean (SD) | 69.7 (19.01) | 75.9 (34.20) |
Admission SOFA score, mean (SD) | 6.5 (2.94) | 6.9 (2.94) |
Patient type (medical), n (%) | 16 (76) | 15 (58) |
Smoking (cigarettes/day), median (IQR) | 20 (12.5–27.5) | 15 (14.5–25.0) |
Alcohol (units/day), median (IQR) | 2 (0–4) | 2 (0–4) |
FTND score, median (IQR) | 5.5 (4–7.75) | 5.0 (4–7) |
AUDIT score, median (IQR) | 5.5 (0.75–12) | 5.0 (1–10.75) |
Receiving nicotine 21 mg/day, n (%) | 13 (62) | NA |
Serum cotinine (ng/ml), median (IQR) | 70.6 (25.8–110) | 80.7 (37.5–126) |
Urine NNAL (pg/ml), median (IQR) | 117.6 (62.5–156.4) | 177.9 (116.9–325.4) |
Inclusion GVH, n (%) | 12 (57) | 14 (54) |